BACKGROUND: Several reports have suggested an increased risk of coronary disease in human immunodeficiency virus (HIV)-infected patients receiving protease inhibitors (PIs). Impaired endothelium-dependent vasodilation is a putative surrogate marker of coronary atherosclerotic disease. METHODS: The present study evaluated the effect of HIV infection and antiretroviral treatment on endothelial vasomotor function, by assessing brachial artery flow-mediated dilation (FMD). A total of 75 HIV-infected patients were compared with 223 control subjects who were presumed to be HIV uninfected. RESULTS: HIV-infected patients had significantly impaired FMD, compared with control subjects (mean +/- SD, 7.3% +/- 4.4% vs. 11.1% +/- 6.3%; P < .0001). When adjustments were made for smoking status, sex, and body mass index, the difference between the 2 groups remained statistically significant (P < .01). In a cross-sectional analysis of the HIV-infected patients, we found significant associations between FMD and current injection drug use, hazardous drinking, HIV load, and alpha-high-density lipoprotein triglyceride levels, but not PI therapy. In a multivariate analysis, only current injection drug use and a lower alpha-high-density lipoprotein triglyceride level were significantly associated with FMD. CONCLUSIONS: HIV-infected patients have significant impairment of endothelial function, and this impairment is worse among those with elevated levels of HIV replication, particularly injection drug users.
BACKGROUND: Several reports have suggested an increased risk of coronary disease in human immunodeficiency virus (HIV)-infectedpatients receiving protease inhibitors (PIs). Impaired endothelium-dependent vasodilation is a putative surrogate marker of coronary atherosclerotic disease. METHODS: The present study evaluated the effect of HIV infection and antiretroviral treatment on endothelial vasomotor function, by assessing brachial artery flow-mediated dilation (FMD). A total of 75 HIV-infectedpatients were compared with 223 control subjects who were presumed to be HIV uninfected. RESULTS:HIV-infectedpatients had significantly impaired FMD, compared with control subjects (mean +/- SD, 7.3% +/- 4.4% vs. 11.1% +/- 6.3%; P < .0001). When adjustments were made for smoking status, sex, and body mass index, the difference between the 2 groups remained statistically significant (P < .01). In a cross-sectional analysis of the HIV-infectedpatients, we found significant associations between FMD and current injection drug use, hazardous drinking, HIV load, and alpha-high-density lipoprotein triglyceride levels, but not PI therapy. In a multivariate analysis, only current injection drug use and a lower alpha-high-density lipoprotein triglyceride level were significantly associated with FMD. CONCLUSIONS:HIV-infectedpatients have significant impairment of endothelial function, and this impairment is worse among those with elevated levels of HIV replication, particularly injection drug users.
Authors: T J Anderson; A Uehata; M D Gerhard; I T Meredith; S Knab; D Delagrange; E H Lieberman; P Ganz; M A Creager; A C Yeung Journal: J Am Coll Cardiol Date: 1995-11-01 Impact factor: 24.094
Authors: A Lafeuillade; M C Alessi; I Poizot-Martin; C Boyer-Neumann; C Zandotti; R Quilichini; L Aubert; C Tamalet; I Juhan-Vague; J A Gastaut Journal: J Acquir Immune Defic Syndr (1988) Date: 1992
Authors: Samir K Gupta; Kieren J Mather; Rajiv Agarwal; Chandan K Saha; Robert V Considine; Michael P Dubé Journal: J Acquir Immune Defic Syndr Date: 2007-08-15 Impact factor: 3.731
Authors: Heather N Grome; Louise Barnett; Cindy C Hagar; David G Harrison; Spyros A Kalams; John R Koethe Journal: AIDS Res Hum Retroviruses Date: 2016-09-14 Impact factor: 2.205
Authors: Erik R Kline; Dean J Kleinhenz; Bill Liang; Sergey Dikalov; David M Guidot; C Michael Hart; Dean P Jones; Roy L Sutliff Journal: Am J Physiol Heart Circ Physiol Date: 2008-05-02 Impact factor: 4.733
Authors: James H Stein; Lauren Komarow; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; Robert A Parker; Francesca J Torriani Journal: J Clin Lipidol Date: 2008-12 Impact factor: 4.766